Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma
Roberta Affatato(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giovanna Damia(Mario Negri Institute for Pharmacological Research)
Cited by 38
Related Papers
Stable CDK12 Knock-Out Ovarian Cancer Cells Do Not Show Increased Sensitivity to Cisplatin and PARP Inhibitor Treatment
|Frontiers in Oncology|2022|8
BRCA1 foci test as a predictive biomarker of olaparib response in ovarian cancer patient-derived xenograft models
|Frontiers in Pharmacology|2024|3